PubRank

Implication of the Autologous Immune System in BCR-ABL Transcript Variations in Chronic Myelogenous Leukemia Patients Treated with Imatinib.

PubWeight™: 0.86‹?›

🔗 View Article (PMID 26359456)

Published in Cancer Res on September 10, 2015

Authors

Geoffrey D Clapp1, Thomas Lepoutre2, Raouf El Cheikh2, Samuel Bernard2, Jérémy Ruby3, Hélène Labussière-Wallet3, Franck E Nicolini3, Doron Levy4

Author Affiliations

1: Department of Mathematics, University of Maryland, College Park, Maryland.
2: Inria, and Université de Lyon, Université Claude Bernard Lyon 1, CNRS UMR 5208, Institut Camille Jordan, Villeurbanne Cedex, France.
3: Centre Hospitalier Lyon, Sud, Pierre-Bénite France and CRCL, Centre Léon Bérard, Lyon, France.
4: Department of Mathematics and Center for Scientific Computation and Mathematical Modeling (CSCAMM), University of Maryland, College Park, Maryland. dlevy@math.umd.edu.

Articles citing this ↘

Mathematical models of breast and ovarian cancers. Wiley Interdiscip Rev Syst Biol Med (2016) 0.75

BCR-ABL transcript variations in chronic phase chronic myelogenous leukemia patients on imatinib first-line: Possible role of the autologous immune system. Oncoimmunology (2016) 0.75

Long-term treatment effects in chronic myeloid leukemia. J Math Biol (2017) 0.75

Dynamical models of mutated chronic myelogenous leukemia cells for a post-imatinib treatment scenario: Response to dasatinib or nilotinib therapy. PLoS One (2017) 0.75